The Renca cell line is a murine (mouse) renal cell adenocarcinoma cell line that originated from a spontaneous tumor in a BALB/c mouse. This cell line is widely used as a preclinical in vitro and in vivo model for studying the biology of renal cell carcinoma and for evaluating potential therapeutic strategies for this type of cancer.

Renca cells have been used to study various aspects of renal cell carcinoma, including tumor growth, invasion, angiogenesis, and metastasis. Additionally, the Renca cell line has been employed to investigate the efficacy of immunotherapies, targeted therapies, and combination treatments in the context of renal cell carcinoma.

One of the advantages of the Renca cell line is its compatibility with syngeneic mouse models, which allows for the study of cancer immunotherapy and immune responses in an immunocompetent host. Researchers can implant Renca cells subcutaneously or orthotopically (in the kidney) in immunocompetent BALB/c mice to generate tumors and study the host immune response, as well as the efficacy of different therapeutic interventions.

It is important to note that while the Renca cell line has proven useful in many aspects of renal cell carcinoma research, it is a mouse-derived cell line, and its relevance to human disease may be limited. Consequently, researchers often complement their studies using Renca cells with investigations involving human renal cell carcinoma cell lines and patient-derived samples.